GX-BP1 Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination
“Our goal with GX-BP1 is to develop it as a combination backbone molecule with any standard therapies for lung cancer as an anti-resistant anti-cancer therapy” said Dr. Jaehyun Choi. “The WCLC data support the potential of GX-BP1 to improve the durability of response when combined with EGFR-targeted therapies and ADCs.”
Share:
More News
Akeso, Inc. announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA). The trial will assess the candidate in patients with advanced malignant solid tumors.
“This financing marks a significant milestone as we execute upon our vision of harnessing the power of macrocycles to transform the treatment of cancer,” said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. “Momentum around our cyclin D1 program has continued to build as CID-165
“FDA Fast Track designation for KST-6051 is an important regulatory milestone for Kestrel, based on the strength of our preclinical data package. This designation will allow us to work more closely with the FDA as we advance KST-6051 through our ongoing Phase 1 study, with the goal of bringing a
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “Today’s deal secures a promising T cell engager and advances GSK’s leadership goals in blood cancer. The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this